D-3899 Decitabine, Free Base, >99%

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 90 mg/mL; soluble in ethanol at 2 mg/mL with warming; soluble in water at 25 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

DCT-104 DCT-103 DCT-102 DCT-101

View the SDS for this product

• Decitabine is a cytosine nucleoside analog and inhibits further DNA methylation after incorporated into DNA. As a consequence, tumor suppressor genes aberrantly silenced after methylation can be reactivated and expressed. Decitabine has shown activity in some hematologic disorders including myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). Leone G., et al. "DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias." Haematologica 87: 1324-1341 (2002).
• Treatment of patients with sickle cell disease (SSD) with subcutaneous decitabine increased fetal hemoglobin (HbF) levels and improved SSD pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity without cytotoxicity. Saunthararajah Y., et al. "Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease." Blood 102: 3865-3870 (2003).
• Treatment of patients with sickle cell disease (SSD) with subcutaneous decitabine increased fetal hemoglobin (HbF) levels and improved SSD pathophysiology such as red cell adhesion, endothelial damage, and coagulation pathway activity without cytotoxicity. Saunthararajah Y., et al. "Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease." Blood 102: 3865-3870 (2003).
• Other CAS numbers previously assigned to Decitabine, Free Base, namely 105597-46-4 and 123795-43-7, have been deleted by CAS and are no longer in use.
• Decitabine is the active ingredient in the drug product sold under the trade name Dacogen®. This drug is currently approved in at least one country for use in patients with MDS.  NOTE: THE DECITABINE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT DACOGEN®, AND IS NOT FOR HUMAN USE.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.